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Certain aspects of diagnosis, prognosis, and treatment of cancer patients are still important challenges to be
addressed. Therefore, we propose a pipeline to uncover patterns of alternative polyadenylation (APA), a hidden
complexity in cancer transcriptomes, to further accelerate efforts to discover novel cancer genes and pathways.
Here, we analyzed expression data for 1045 cancer patients and found a significant shift in usage of poly(A) signals
in common tumor types (breast, colon, lung, prostate, gastric, and ovarian) compared to normal tissues. Using
machine-learning techniques, we further defined specific subsets of APA events to efficiently classify cancer
types. Furthermore, APA patterns were associated with altered protein levels in patients, revealed by antibody-
based profiling data, suggesting functional significance. Overall, our study offers a computational approach for use
of APA in novel gene discovery and classification in common tumor types, with important implications in basic
research, biomarker discovery, and precision medicine approaches.
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Despite the flow of new information provided by genome and
transcriptome sequencing studies, certain aspects of diagnosis,
prognosis, and treatment of cancer patients are still important
challenges to be addressed. Therefore, a better understanding of the
complexity of cancer necessitates characterization of “less obvious but
potentially important” changes that we generally fail to detect or
consider to be noise in conventional experimental setups. From
this perspective, gene expression studies face a key bottleneck;
conventional methods are generally not tailored to detect nor quantify
3′ isoforms generated by alternative polyadenylation (APA) [1]. This
may negatively impact our ability to discover cancer-related genes and
comprehensively understand critical molecular mechanisms underlying
disease progression.
APA isoforms are formed as a result of endonucleolytic cleavage of
the nascent RNA at alternative poly(A) sites [2]. APA is tightly
regulated and is responsive to proliferative, tissue-specific, or
developmental cues [3]. APA-generated short or long 3′ untranslated
region (UTR) isoforms harbor different cis-elements where
microRNAs (miRNAs) and/or RNA-binding proteins bind [4].
Consequently, APA isoforms have different stability, localization, and
translation efficiency, all of which significantly modulate protein
levels and/or activity. Considering that majority of human genes havemultiple poly(A) sites in their 3′-ends [5], APA constitutes an
important but less understood layer of complexity in gene expression
regulation. Recently, deregulation of APA has gained increasing
interest in cancer research because APA emerges as a novel mechanism
to activate oncogenes, generally by 3′UTR shortening and loss of
repressive cis-elements. For example, 3′UTR shortening of CCND1
(Cyclin D1) mRNA prevents the miRNA-mediated repression and
causes further increase in CCND1 levels, which correlate with
decreased overall survival of patients [6]. Insulin-like growth factor 2
mRNA binding protein 1 (IGF2BP1) also goes through a shortening
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oncogenic transformation [7]. In addition, our group reported
hormone-responsive APA, where estrogen treatment resulted with
upregulation and 3′UTR shortening of cell division cycle 6 (CDC6),
a major regulator of DNA replication, in breast cancer cells. Thus, as a
result of APA, the short CDC6 isoform was linked to higher CDC6
protein levels and increased S-phase entry [8].
While numerous cases of 3′UTR shortening have been linked to
increased protein levels and oncogene activation [7], consequences of 3′
UTR shortening on protein levels and functionsmay be complex. It turns
out that 3′UTR shortening may also lead to changes in secondary
structure of the mRNA, exposing hidden cis-elements, this time leading
to decreased protein levels [9]. In addition, 3′UTR isoforms can have
different functions as scaffolds to tether RNA-binding proteins that alter
the localization and even function of the translated protein [10].
Alternatively, in cases where proximal poly(A) signals are within introns or
coding exons, truncated proteins can be generated with potentially
different and/or opposing functions (reviewed in [11]). Hence, APA can
contribute to the oncogenic phenotype through various mechanisms [7].
Despite these potential impacts, APA-generated isoforms are generally
undetected simply because we do not look for them in conventional gene
expression analyses. Here, we report a meta-analysis pipeline for APA
isoform discovery to improve cancer-related gene discovery efforts.
Identification of cancer specific APA isoforms is likely to have important
implications in basic cancer research and biomarker discovery fields. We
anticipate our proposed comprehensive approach to be applicable to other
malignancies where expression datasets are available.
Materials and Methods
Datasets
For the discovery datasets, breast, colon, lung, ovarian, and prostate
cancer patient data (GSE2109), as part of Expression Project for
Oncology from National Center for Biotechnology Information
Gene Expression Omnibus (GEO), were utilized. Data for gastric
cancer and normal samples (GSE29272) were obtained from GEO.
Breast cancer patient data included 318 patients: 69 patients
(21.7%) were diagnosed as estrogen receptor negative (ER−), 146
(45.9%) were ER+, and 12 patients (3.8%) were diagnosed with
triple-negative breast cancer. Colon cancer patient data included 249
cancer samples: 203 patients (81.5%) were diagnosed with
adenocarcinoma, 30 (12%) with mucinous carcinoma, 15 (6%)
with carcinoma arising in a villous adenoma, and 1 (0.4%) with signet
ring cell carcinoma. Gastric cancer patient data included 134 patients:
62 patients (46%) were diagnosed with cardia adenocarcinoma, and
72 (54%) were diagnosed with noncardia adenocarcinoma. Lung
cancer patient data had 105 samples: 32 patients (31%) were diagnosed
with squamous cell carcinoma, 29 (28%) with lung adenocarcinoma, and
13 (13%) with bronchioloalveolar carcinoma. Ovarian cancer patient data
included 166 samples: 28 patients (16.9%) were diagnosed with papillary
serous carcinoma, 27 (16.3%) with papillary serous adenocarcinoma, and
15 patients (9%) with endometrioid cancer. Prostate cancer patient data
had 73 samples: 63 patients (86%) were diagnosed as acinar type
adenocarcinoma and 10 (14%) as adenocarcinoma-NOS.
Detection and Quantification of APA Events
APADetect tool [12] was used to detect and quantify APA events in
common cancers. CEL files of Human Genome U133A (HGU133A,
GPL96) and U133 Plus 2.0 arrays (HGU133Plus2, GPL570) were
analyzed to identify intensities of probes that were grouped based onpoly(A) site locations extracted from PolyA_DB [13]. For each
transcript, mean signal intensities of proximal and distal probe sets
were calculated. The ratio of proximal probe set mean to the distal
probe set was called the “short to long” ratio (SLR). SLR values of
cancer samples were compared to those of corresponding normal
tissue samples. Next, SLR values were further subjected to
significance analysis of microarrays (SAM) [14], as implemented by
the TM4 Multiple Array Viewer tool [15], for statistical significance
after log normalization. A fold change filter further eliminated APA
events below a determined threshold (SLR N1.5 for shortening events
or SLR b0.66 for lengthening events). SLR values reported in at least
85% of the samples were included in the subsequent analysis and
classification pipeline.
Feature Selection
Correlation-based feature selection subset evaluation (CfsSubsetEval)
method was used to avoid overfitting and “curse of dimensionality”
problems [16,17], as implemented in WEKA data mining software
[18]. CfsSubsetEval assessed the performance of a subset of attributes
(i.e., SLR values) based on predictive ability and redundancy. The
subset space of all the attributes were searched using the BestFirst
algorithm with default parameters in WEKA [19]. The attributes were
evaluated using 10-fold cross validation. To increase specificity and
sensitivity, we selected SLR values that were listed as best attributes in at
least 5 of the 10 cross-validations. This group of APA events was
identified as best first list (BFL) (Supplementary Tables 1, 2). Heatmap
illustration of APA events in BFLwas done with a hierarchical clustering
implemented in Multiple Array Viewer tool [15]. For the hierarchical
clustering based on Pearson correlation coefficient, average linkage-
based gene tree with optimized gene leaf order was used as parameter.
For a distance-based comparison of the samples, we constructed
color-coded gene distancematrices for normal and cancer samples using
Pearson correlation coefficient (Supplementary Figure 1).
Random Forest
Random forest classifiers [20,21] were trained using SLR values in
BFL. Both the selection of features and training of random forest
classifiers were conducted using only the discovery (i.e., training)
datasets. The classification accuracy was assessed in independent
validation datasets. Use of random forest classifiers was also important
for error balancing which can be critical for cancer studies as the
number of control samples is usually smaller than the number of
cancer samples. Confusion matrix for cancer type analysis was
constructed as an output of random forest analysis.
Principle Component Analysis (PCA)
PCA [22] was performed to visualize the SLR-based separation
between samples in a lower dimensional space. PCA, as implemented in
WEKA, was used with default parameters. Dimensionality reduction was
accomplished by choosing the top two principle components in the
normal versus cancer separation and top three principle components in
the cancer classification. PCA results were then visualized usingGraphPad
Prism 6 software and Gnuplot (http://gnuplot.sourceforge.net).
Ontology and Network Analysis
Significant APA events (SLRs b0.66 or N1.5) were analyzed by
Gene Set Enrichment Analysis (GSEA) (http://www.broadinstitute.
org/gsea/index.jsp) [23] and Molecular Signature Database [23].
Network database STRING (http://string-db.org) [24] was used to
find potential networks in the APA-regulated transcript lists.
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Antibody-based protein profiling using IHC data from Human
Protein Atlas database (http://www.proteinatlas.org) [25] was used to
evaluate the protein levels of significant BFL genes. Staining
intensities in normal tissues and cancer samples were presented as
pathology-based annotation of protein expression levels (low,
medium, high).
Results
Microarray data can be retrospectively analyzed to discover
differential APA isoforms using algorithms based on probe intensities
and poly(A) site location information. Earlier, we have developed and
successfully implemented a meta-analysis tool for APA isoform
discovery: “APADetect” [8,12] (described in “Materials and
Methods”). To decipher deregulated APA profiles, we compiled a
pool of cancer patient expression data representing six common cancer
types (breast, colon, gastric, lung, ovary, and prostate cancers) [26] from
the Expression Project for Oncology and National Center for
Biotechnology Information GEO databases (Supplementary Table 3).
Given that APA is tissue specific [27], independent datasets for
corresponding normal tissues were included in the APA detection
pipeline (Supplementary Table 4). Overall, we analyzed expression data
for a total of 1045 cancer patients (318 for breast, 249 for colon, 134 for
gastric, 105 for lung, 166 for ovarian, and 73 for prostate cancers)
compared to 479 corresponding normal tissue samples (81 for breast,
81 for colon, 134 for gastric, 104 for lung, 38 for ovary, and 41 for
prostate). For each cancer/tissue type, CEL files were analyzed by
APADetect tool followed by SAM analysis (Figure 1A).
We identified a shift toward proximal poly(A) site selection in
breast (158 of 222, %71), gastric (58 of 105, %55), and prostate
cancers (96 of 104, 92%) compared to their corresponding normal
tissues, whereas distal poly(A) selection was more prominent in colon
(142 of 225, 63%), lung (197 of 216, 91%), and ovarian cancers (172
of 225, 76%) (Figure 1B).
Network and ontology analyses of significant APA events (SLR values
N1.5 or b0.66, n = 458) were investigated for biological significance
with STRING and GSEA tools [23,24,28] (Figure 2, A and B).
Cancer-specific selection of proximal or distal poly(A) site was mostly
enriched for RNA-related process (i.e., polyA RNA binding, RNA
binding) and pathways that may be associated with the proliferative
state of cells, suggesting APA events to potentially modulate a diverse
network of downstream events (Figure 2, A and B).
Using SLR Values for Normal Versus Cancer Discrimination
Following the discovery of global APA profiles, we investigated
whether subgroups of identifier APA events can discriminate normal
and cancer samples. Therefore, we used feature selection and
classification methods available in WEKA data mining software
[18]. CfsSubsetEval and random forest methods (see “Materials and
Methods” for details) showed that normal and different cancer
samples were distinguished using a total of 63 unique attributes (BFL)
(Supplementary Tables 1 and 2). In particular, the number of
attributes with classifier potential was 16 for breast, 9 for colon, 11 for
gastric, 14 for lung, 11 for ovarian, and 13 for prostate. Several APA
events (e.g., TOP2A, BGN, RPL13) were redundant in more than
one cancer type. Heat maps illustrating color-coded levels of increased
or decreased SLR values, representing 3′UTR shortening or
lengthening, in cancer patients compared to normal tissues are
shown in Figure 3A. Next, we applied PCA using SLR values of
transcripts in BFL and produced visualizations in which key APA
events between normal tissues and cancer types were represented by apoint in the plane formed by two principal axes. In the discovery
set, the first two principle components explained 41%, 56%, 68%,
72%, 71%, and 69% of the total variance in breast, colon, gastric,
lung, ovarian, and prostate cancer samples, respectively (Figure 3B,
Supplementary Table 5). Gene distance matrices for normal and
cancer samples using Pearson correlation coefficient are given in
Supplementary Figure 1.
To further test the discriminating power of these APA events,
random forest classifiers trained in discovery datasets were then
applied to an independent validation set (Supplementary Table 3).
The true-positive rate for distinguishing cancer samples from their
corresponding normal tissues was quite significant using these
classifiers. The lowest true-positive rate was 0.82 (F value, 0.81) in
gastric cancer, and the highest was 1.00 in prostate cancers
(Supplementary Table 6). For the validation set, PCA showed
that the first two principle components explained 45%, 58%, 68%,
61%, 56%, and 74% of the total variance in breast, colon,
gastric, lung, ovary, and prostate samples, respectively (Figure 3C,
Supplementary Table 7).
Considering that APA is tissue specific [3,29], we also tested
whether we can discriminate individual cancer types from a mixed
pool of other cancers. Therefore, an additional CfsSubsetEval was
performed to find the best attribute list for cancer classification. The
feature selection on the discovery set identified 21 best first attributes
for cancer discrimination (Supplementary Table 8). These attributes
were then used to build a classifier model by random forest for the
validation set of cancer patients. Our classifier model distinguished all
six cancer types from each other. The lowest F value (0.777) was for
lung cancer, where 12 of 19 (63%) of patients were correctly
identified as lung cancer. F values for breast, colon, gastric, ovarian,
and prostate cancers were; 0.95, 0.96, 0.95, 0.96, and 1.00,
respectively (Figure 4A). PCA showed cancer type discrimination
represented by three principal axes (Figure 4B, Supplementary Movie 1),
suggesting good generalization performance of the classifiers. Normal
tissue samples were also successfully distinguished using another
classifier of 54 APA events (Supplementary Figure 2, Supplementary
Tables 8 and 9).
Significance of APA Events in Cancer
Given the classifier power of APA events, a test group in BFL
was individually investigated in detail for biological relevance. First,
the genomic positions of active poly(A) sites in relation to gene
structures were examined (Supplementary Table 2). Majority of
alternative poly(A) site usage cases that have classifier abilities for
common cancer types were in 3′UTRs (47 of 63); 11 of APA events
resulted with activation of proximal poly(A) sites in introns and 5
poly(A) sites in coding exons (Figure 5A). Among these APA events,
highest and lowest SLR values were plotted for cancer patients
compared to normal tissue samples. SLR values indicative of APA in
patient groups were indeed all statistically significant compared to
normal tissue controls (Figure 5A) (P b .0001).
Next, because proximal poly(A) site usage is generally associated
with higher protein levels due to loss of repressive cis-elements, we
asked whether APA isoform variation has any potential effects on
resulting protein levels in cancer patients. Therefore, protein levels of
the test group of APA events were investigated in the Human Protein
Atlas (http://www.proteinatlas.org/cancer) database [25] where
protein expression data are derived from antibody-based protein
profiling using IHC in normal tissue and cancer patient samples. For
Figure 1. (A) Studyworkflow. CEL files ofmicroarray data for normal (479) and cancer samples (1045) were processedwith the previously developed
APADetect tool [12].U133Plus2andU133Aplatformsweresimultaneously analyzed throughAPADetect, increasingpotential samplenumbers.Poly(A)
genomic position information was extracted from PolyA_DB. Probe intensities grouped by poly(A) site positions were processed through probe,
intensity, and distal filters, which exclude outliers. LogSLRmatrix file is the output filewhere individual APA eventswere assigned anSLR. APAevents,
whichweredetected inat least85%ofsamples,were then run throughSAM.To identify theattributes thathave thebestability todiscriminatebetween
normal and cancer samples, correlation-based feature selection was compiled with BestFirst algorithm and 10-fold cross validation. Significant
attributeswere used in random forest and principle component analyses for classifying cancers compared to normal tissues and specific cancer types
amongothercancers. (B)Volcanoplots forallAPAeventsdetected insixdifferentcancer typescomparedtocorrespondingnormal tissues.XandYaxes
represent SLR of APA events in cancer and normal samples. Red dots represent proximal poly(A) usage, blue dots represent distal poly(A) usage, and
gray dots represent insignificant SLR values in cancer patients compared to normal tissue. Bar graphs show the number of APA events.
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Figure 2. Network and ontology enrichment analysis for significant APA events. (A) STRING analysis illustrated multiple clusters,
numbered according to GO Biological Process classes shown below. Unconnected proteins are excluded from the illustration. (B) GSEA
analysis indicates enriched biological processes with highest log(P) values. FDR q values indicate the false-discovery rate for each
biological process.
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associated with varying degrees of high protein staining compared
to normal tissues (Figure 5B). For example, increased proximal
polyadenylation pattern of topoisomerase II alpha (TOP2A) was in
agreement with high level of staining in breast and lung cancers.
Another significant case of APA was detected for ribosomal protein
L13 (RPL13) in breast, lung, and ovarian cancers where IHC
data also suggested medium to high level of staining in all three
types of cancer patients compared to normal tissue. Likewise, WD
and tetratricopeptide repeats 1 (WDTC1) with 3′UTR shortening
in lung cancers had high level of IHC staining in lung cancer
patients.We then investigated staining patterns of proteins whose
transcripts did not appear to be regulated by APA (SLR = 1). A
randomly selected group of (SLR = 1) transcripts had similar protein
staining patterns in normal and in cancer samples, further
strengthening our approach (Supplementary Figure 3).
Interestingly, high-level protein staining was also detected for
some cases [e.g., SET nuclear proto-oncogene (SET)], for which 3′
UTR lengthening was observed in cancer cells, suggesting longer
isoforms to enhance translation (Supplementary Figure 3A). This is
consistent with a previous observation on 3′UTR shortening to
potentiate translational repression due to altered secondary
structure of the mRNA, exposing miRNA binding sites only on
Figure 3. (A) Characteristic signatures of alternative polyadenylation cases listed in BFL in different cancer types compared to normal
tissues. Heatmap key was adjusted in each sample set for optimal visualization and does not reflect the absolute SLR values
(Supplementary Table 1). Red and green colors indicate increased or decreased SLR values (N1.5 fold or b0.5) in cancers compared to
control tissues. Red color signifies use of proximal poly(A) sites, whereas green color signifies use of distal poly(A) sites. APA events are
classified as proximal (Prox) or distal (Dist) poly(A) site usage. Each column represents a patient, and each row represents proximal or
distal poly(A) site usage. Unsupervised clustering differentiated APA events. (B) Two-dimensional PCA of normal and cancer samples for
discovery set using BFL. (C) PCA in independent validation sets using APA events in BFL.
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detected in our analysis for proline rich nuclear receptor coactivator
1 (PNRC1), which is a nuclear receptor coactivator that also
interacts with GRB2 (an adapter protein involved in growth factor/
Ras-mediated signaling pathways) and suppresses GRB2-mediated
Ras/MAP-kinase activation. Therefore, PNRC is a potential tumor
suppressor candidate, and in fact, its expression is reported to be
low in breast cancers [30]. Other cases of distal poly(A) site usage
and corresponding protein levels in cancer samples are shown in
Supplementary Figure 3A.
We identified another group of APA events where active polyadenyla-
tion sites reside in introns or coding exons [e.g., SLU7 homolog, splicing
factor (SLU7)] (Supplementary Figure 4A). Selection of these sites
suggests APA to be coupled to alternative splicing and lead to production
of truncated proteins. In the case of SLU7, activation of the exonic
poly(A) siteHs.435342.1.9 leads to a ~70 aa truncation at theC-terminus
of the protein. Interestingly, SLU7 itself is a known splicing factor that
binds to the C13orf25 primary transcript in which the polycistronic
oncomiRmiR-17-92 resides [31].Hence, alterations of the protein length
may have functional significance. Another case, a more redundant APAcase, was forTOP2A which had increased selection of a proximal poly(A)
site within Exon 26, Hs.156346.1.29 (Supplementary Figure 4B).
Activation of this coding sequence poly(A) site leads to 384 amino acid
truncation at the C-terminus. Therefore, exonic and intronic poly(A)
activation cases are of great interest to investigate whether protein
activities are altered, specifically when these proteins are being considered
as drug targets. It is also important to be aware of these isoforms during
the choice of antibodies for detection purposes.
Discussion
In cancer cells, deregulated APA can be an important source of
isoform diversity which may be overlooked in conventional gene
expression analyses. For example, sequencing is becoming the
standard method for transcriptome analysis, but random priming
and differential PCR amplification lead to read depletion near 3′
ends, negatively affecting APA isoform discovery [32] (also reviewed
in [11]). Our proposed approach takes advantage of microarray
platforms where probe sets are generally designed from 3′UTRs,
making it possible to identify APA events via altered signal intensities
near poly(A) sites. A drawback to microarray data use is that only
Figure 4. Classification of individual cancer types from amixed pool of other cancers. (A) Our classifier model consisting of 21 APA events
distinguished all 6 cancer types from each other. Confusion matrix demonstrates the performance of the classification model where
percentage of correct calls, number of patients, and F values are indicated. (B) PCA showed cancer type discrimination represented by
three principal axes (Supplementary Movie 1).
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Despite this limitation, an important advantage of our probe-based
approach is rapid and simultaneous analysis of publicly available datasets.
In addition, our pipeline presented here offers distinct and reproducible
results to reveal APA-generated diversity in cancer cells [8,12].
Here, we show cancer-specific APA patterns. Our results indicate
altered use of proximal or distal poly(A) sites in cancer transcriptome
compared to normal tissue. While some of the APA-regulated
genes we identified have already been implicated in tumorigenesis
(e.g., TOP2A, EIF5B), a consequential link between APA and how
these isoforms may contribute to tumorigenesis is not currently
known. In addition, for certain oncogene activation or tumor
suppressor inactivation cases, APA may provide insight into howFigure 5. (A). BFL APA events and exemplary log SLR values for prox
type. Unpaired t test with Welch's correction was used to compare g
Protein levels detected by IHC in cancer and normal samples are show
Human Protein Atlas [25]. Sample size indicates the number of cance
high) as pathology-based annotation of protein expression levels.protein levels/functions are altered in cancer cells. For example,
shortened or lengthened 3′UTRs may lose or retain binding sites for
trans-factors, which may impact the level and/or subcellular
localization of the resulting protein. Alternatively, activation of
intronic or coding sequence poly(A) sites may generate isoforms that
differ at the 3′ends with different coding potentials.
We have to note the possibility that there may be other more
proximal or distal poly(A) sites on transcripts; however, either they are
not activated in that specific tissue or the probe distribution on
microarrays does not allow detection of such poly(A) sites. Therefore, it
is possible that APA isoforms may be more widespread in these
and other cancer types. Indeed, an earlier work by Xia et al. presented
APA isoform diversity in 358 TCGA pan-cancer tumor/normal pairs inimal and top distal poly(A) site usage cases plotted for each cancer
roup means. **** indicates statistical significance (P b .0001). (B)
n. Data for antibody-based protein profiling was extracted from the
r and normal samples scored for staining intensities (low, medium,
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582 Alternative Polyadenylation Patterns in Cancer Begik et al. Neoplasia Vol. 19, No. 7, 2017a different set of tumor types (bladder urothelial carcinoma, head and
neck squamous cell carcinoma, lung squamous cell carcinoma, lung
adenocarcinoma, breast invasive carcinoma, kidney renal clear cell
carcinoma, uterine corpus endometriosis carcinoma) using an
APA-specific algorithm (DaPars) to analyze RNA-seq data [33].
In summary, our approach and results have two significant
implications: 1) revealing APA isoform variation in cancer cells may
help the discovery of as of yet unknown but potentially important
novel cancer-related genes/pathways, and 2) tissue- and cancer type–
specific APA may provide novel targets for diagnostic and prognostic
purposes, which could help optimize patient outcomes using
precision medicine approaches.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2017.04.008.
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